Gilead Sciences provides updates on access to twice-yearly and investigational once-yearly lenacapavir for HIV prevention.
Gilead Sciences press releases
Gilead and PAHO announce milestone partnership to accelerate access to twice-yearly lenacapavir for HIV prevention across Latin America and the Caribbean
Gilead Sciences, Inc. announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as PrEP across all PAHO Member States in Latin America and the Caribbean. Through PAHO’s Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led efforts toward adoption and implementation, as part of the broader efforts to end the epidemic across the region.
Gilead accelerates global access planning for investigational once-yearly lenacapavir for HIV prevention
Gilead Sciences, Inc. announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as PrEP. The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while the Phase 3 PURPOSE 365 trial is ongoing.
Related HIV and Co-Infections News
-
[Press release] UNAIDS to support Fiji as it declares HIV a national crisis and puts in new measures to strengthen the response
-
Health Policy Watch | LGBTIQ groups in repressive countries are worst affected by US funding cuts
-
[Report] ECDC | Overview of the provision of prevention and testing for HIV and STIs for sex workers in EU/EEA
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.